US Patent Issued to Regeneron Pharmaceuticals on Sept. 15 for "Target-based method for high-throughput and subclass specific IgG glycan profiling in human plasma" (New York, Connecticut Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,736,541, issued on Sept. 15, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Target-based method for high-throughput and subclass specific IgG glycan profiling in human plasma" was invented by Yunlong Zhao (Scarsdale, N.Y.), Shivkumar Raidas (New City, N.Y.), Yuan Mao (Hartsdale, N.Y.) and Ning Li (New Canaan, Conn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This application relates to methods for identifying a glycosylated peptide biomarker in a sample. In particular, the application relates to methods for identifying an N-glycan profile of a protein in a sample."

The patent was filed on Jan. 17, 2024, under Application No. 18/...